# Vyant Bio, Inc.

Vyant Bio, Inc. is a company headquartered in Cherry Hill,, NJ, United States.

## Company overview

- **Legal name:** Vyant Bio, Inc.
- **Former names in filing history:** CANCER GENETICS, INC (2011-12-30 to 2021-03-31); CANCER GENETICS INC (2006-01-10 to 2010-11-01)
- **Classification:** Company
- **Industry (SIC):** 8071 — Services-Medical Laboratories
- **Headquarters:** Cherry Hill,, NJ, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0001349929

## About

Vyant Bio, Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001349929, and its reported industry is Services-Medical Laboratories. In 10-K filed on 2023-03-31, it reported annual revenue of USD 666,000; net income of USD -22,690,000; total assets of USD 15,205,000 for the fiscal period ended 2022-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2022 (period ended 2022-12-31)

- **Revenue:** $666,000 (USD 666,000)
- **Net income:** -$22.7M (USD -22,690,000)
- **Total assets:** $15.2M (USD 15,205,000)
- **Cash and equivalents:** $10.0M (USD 10,041,000)
- **Operating cash flow:** -$13.7M (USD -13,681,000)

### FY2021 (period ended 2021-12-31)

- **Revenue:** $1.1M (USD 1,148,000)
- **Net income:** -$40.9M (USD -40,859,000)
- **Total assets:** $37.6M (USD 37,636,000)
- **Cash and equivalents:** $20.6M (USD 20,608,000)
- **Operating cash flow:** -$17.0M (USD -16,993,000)

### FY2020 (period ended 2020-12-31)

- **Revenue:** $5.8M (USD 5,751,000)
- **Net income:** -$8.0M (USD -8,001,000)
- **Total assets:** $8.3M (USD 8,348,000)
- **Cash and equivalents:** $2.4M (USD 2,444,000)
- **Operating cash flow:** -$5.4M (USD -5,371,000)
- **Later filings:** Revenue, Net income, Total assets, Cash and equivalents, Operating cash flow: shown as originally filed; later filings report different values for the same periods.

### FY2019 (period ended 2019-12-31)

- **Revenue:** $7.3M (USD 7,305,000)
- **Net income:** -$6.7M (USD -6,708,000)
- **Total assets:** $14.9M (USD 14,904,000)
- **Cash and equivalents:** $3.9M (USD 3,880,000)
- **Operating cash flow:** -$8.7M (USD -8,660,000)

## Recent SEC filings

- Form DEF 14A — filed 2023-08-16 — period 2023-08-15
- Form 8-K — filed 2023-05-10 — period 2023-05-09
- Form 8-K — filed 2023-04-24 — period 2023-04-24
- Form 10-K — filed 2023-03-31 — period 2022-12-31
- Form 8-K — filed 2023-03-24 — period 2023-03-24
- Form 8-K — filed 2023-03-22 — period 2023-03-20
- Form 8-K — filed 2023-03-15 — period 2023-03-13
- Form 8-K — filed 2023-03-13 — period 2023-03-07
- Form 8-K — filed 2023-02-03 — period 2023-01-31
- Form 8-K — filed 2023-01-05 — period 2022-12-30
- Form 8-K — filed 2023-01-04 — period 2023-01-04
- Form 8-K — filed 2022-12-19 — period 2022-12-16

---

Updated: 2026-10-23T20:06:36Z

Canonical page: https://altss.com/profile/vyant-bio-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology